Key facts
- This page summarizes John D. Morberg's Form 4 filing for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Jan 2024, 14:26.
John D. Morberg - 18 Jan 2024 Form 4 Insider Report for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- LFCR
- Reported as of
- 18 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Jan 2024, 14:26:42 UTC
- Prior SEC filing
- 05 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Aaron Perlitsh, Attorney-In-Fact for John Morberg
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
John D. Morberg filed Form 4 for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) on 22 Jan 2024.
Change
- Previous filing in this sequence was filed on 05 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LFCR
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +17,500
- Change %
- +15%
- Price
- Shares after
- 131,900
- Date
- 18 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
LFCR
transaction
Common Stock
Tax liability
- Transaction value
- Shares
- -6,283
- Change %
- -4.8%
- Price
- Shares after
- 125,617
- Date
- 18 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LFCR
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -17,500
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 18 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,500
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
Footnote F2
The restricted stock units vested on January 18, 2024.